Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies

Blood

Volumn 91, Issue 11, 1998, Pages 4051-4055

  Hattori, Koichi ^b   Hirano, Takao ^b   Miyajima, Hiroaki ^b   Yamakawa, Norifumi ^b   Tateno, Masatoshi ^b   Oshimi, Kazuo ^b   Kayagaki, Nobuhiko ^b   Yagita, Hideo ^b   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLOGRAFT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CELL DEATH; GRAFT VERSUS HOST REACTION; LIGAND BINDING; LYMPHOCYTE SUBPOPULATION; MEDIATOR RELEASE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TISSUE INJURY;

EID: 0032100478     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4051     Document Type: Article

References (21)

1. Martin PJ, Hansen JA, Storb R, Thomas ED: Human marrow transplantation: An immunological perspective. Adv Immunol 40:379, 1987
2. Ferrara JLM, Deeg HJM: Graft-versus-host disease. N Engl J Med 324:667, 1991
3. Vogelsang, GB, Hess AD: Graft-versus-host disease: New directions for a persistent problem. Blood 84:2061, 1994
4. Gleichemann E, Pals ST, Rolink AG, Radaszkiewics T, Gleichmann H: Graft-versus-host reactions: Clues to the etiopathology of a aspectrum of immunological diseases. Immunol Today 5:324, 1984
5. Tracey KJ, Wei H, Manogue KR, Pong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran, RS, Cerami A, Lowry SF: Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 167:1211, 1988
6. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411, 1992
7. Holler E, Kolb HJ, Möller A, Kempeni J, Loesenfeld S, Pechumer H, Lemacher W, Ruckdeschel G, Gleixner B, Riedner C: Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 75:1011, 1990
8. Piguet PF, Grau GE, Allet B, Vassalli P: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 166:1280, 1987
9. Hervé P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E, Lioure B, Roche C, Vilmer E, Demeocq F, Kuentz M, Chan JY: Phage I-II trial of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus host disease. Blood 79:3362, 1992
10. Daniel ES, Martin FB, Thomas WF, Kim M-F, Emily G, Klaus P, Tak WM, Pamela SO: TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 158:5185, 1997
11. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
12. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415. 1993
13. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-mached allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
14. Charles SV, Phuong N, Andrei S, Joern D, Keith E: A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157:5387, 1996
15. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolyric acitivity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657, 1996
16. Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Yagita H, Okumura K: Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA 94:3914, 1997
17. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Huffman R, Rubin BY: The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia. Synergism of tumor necrosis factor and Interferon-γ. J Immunol 136:4487, 1986
18. Murphy M, Perussia B, Trinchieri G: Effects of recombinant tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 69:467, 1988
19. Jacobson FW, Rothe M, Rusten L, Goeddel DV, Smeland EB, Veiby OP, Slørdal L, Jacobson SEW: Role of the 75-kDa tumor necrosis factor receptor: Inhibition of early hematopoiesis. Proc Natl Acad Sci USA 91:10695, 1994
20. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K: A metalloproteinase inhibitors prevents lethal acute graft-versus-host disease in mice. Blood 90:542, 1997
21. Sytwu HK, Liblau RS, McDevitt HO: The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 5:17, 1996